Abstract
Importance: Cognitive impairment is the greatest single source of unmet need identified by stroke survivors. Knowledge of the factors that influence cognitive prognosis will lead to better preventive and rehabilitation strategies. Objective: To identify the factors that influence general cognitive function, memory and executive function in the first year after ischemic stroke. Design: Single centre longitudinal observational study. Setting: Hospital stroke service. Participants: A cohort of 179 patients identified within 7 days of first symptomatic ischaemic stroke were enrolled into a longitudinal cognitive study, STRATEGIC. General cognitive function, episodic memory and executive function were assessed in the first three months and again at one year after stroke. Lesion topography was defined by imaging (n=152) performed in the acute period. Cognitive evaluation was repeated at one year in 141 participants. Main Outcome Measures: Montreal Cognitive Assessment (MoCA) score at 1 year. Verbal free recall (Free and Cued Selective Reminding Test) and Digit Symbol Substitution Score provided secondary outcome measures of episodic memory and executive function respectively. Results: At 50+-19 days after stroke, diabetes mellitus and smoking were associated with MoCA score independent of other risk and demographic factors. Lesion vascular territory was independently associated with memory while white matter lesion burden was associated with executive function. In contrast to other risk factors, ischaemic heart disease was associated with change in cognitive scores and MoCA score at one year but not MoCA score at 3 months. IHD was the only factor significantly associated with change over time. This association was significant independent of other factors. Conclusions and Relevance: Associations between post-stroke cognition, and age, diabetes, smoking and white matter lesions, are likely to reflect the general effects of these factors on brain structure and function. These risk factors are not associated with change in cognitive function between 3 months and one year. In contrast, pre-existing ischemic heart disease was associated specifically with change in cognition over time. On average, patients with IHD showed decline in MoCA scores between 3 and 12 months while those free of IHD showed improvement. Intervention for IHD, alongside best-care stroke rehabilitation, merits investigation as a strategy to improve cognitive prognosis after stroke.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03982147
Funding Statement
This study was supported by the Medical Research Council, UK, grant reference MR/K022113/1 and the European Commission Horizon 2020 Programme (grant agreement no. 667375). This report represents independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available for sharing with qualified investigators and will be shared, in anonymized form, upon request, in accordance with the terms of the study ethical approvals.
